2022
Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone?
Rodriguez JV, Tormey CA. Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone? Transfusion And Apheresis Science 2022, 61: 103402. PMID: 35288056, DOI: 10.1016/j.transci.2022.103402.Peer-Reviewed Original ResearchConceptsTransfusion-associated graftTA-GVHDHost diseaseCellular blood productsHigh mortality rateWhite blood cellsBlood productsEffective treatmentMortality rateTransfusion communityHigh mortalityMedical literatureBlood cellsDiseaseDevastating diseaseGraftLeukocytesLeukoreductionQuantitative reductionHospitalMortality
2014
The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders
Gehrie EA, Tormey CA. The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders. Transfusion Medicine And Hemotherapy 2014, 41: 420-429. PMID: 25670929, PMCID: PMC4280450, DOI: 10.1159/000369109.Peer-Reviewed Original ResearchRed blood cellsPatient populationInfluence of ClinicalDevelopment of antibodiesImportant clinical consequencesDiverse patient populationsBlood group antigensRBC alloimmunizationChronic transfusionRBC alloantibodiesHyper respondersClinical circumstancesClinical consequencesAlloimmunizationMedical literatureTransfusionAlloantibodiesGroup antigensRespondersBlood cellsTransfusion medicinePatientsBiological factorsIndividualsPregnancy